| Citation: |
TIAN Zhuang, ZHANG Shuyang. Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 801-806. DOI: 10.12290/xhyxzz.2024-0292
|
In the past few years, there have been many breakthroughs in the treatment of heart failure, especially in drug therapy. The classification of chronic heart failure and treatment methods for heart failure and its complications are also constantly updated. In order to apply these achievements to a better diagnosis and treatment of heart failure patients in China, Chinese Society of Cardiology, Chinese Medical Association, Chinese College of Cardiovascular Physician, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology have jointly published the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024, which comprehensively updates the new consensus and evidence-based treatment in the field of heart failure. These contents are of great significance for guiding diagnosis and treatment of heart failure patients in clinical practice. This article, therefore, aims to interpret the main updated contents and key points to provide readers with a better understanding of its key information.
| [1] |
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018[J]. Chin J Cardiol, 2018, 46(10): 760-789. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004
|
| [2] |
中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275. https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202404009.htm
Chinese Society of Cardiology, Chinese Medical Association, Chinese College of Cardiovascular Physician, Chinese Heart Failure Association of Chinese Medical Doctor Association, et al. Chinese guidelines for the diagnosis and treatment of heart failure 2024[J]. Chin J Cardiol, 2024, 52(3): 235-275. https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202404009.htm
|
| [3] |
Halliday B P, Wassall R, Lota A S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy(TRED-HF): an open-label, pilot, randomised trial[J]. Lancet, 2019, 393(10166): 61-73. DOI: 10.1016/S0140-6736(18)32484-X
|
| [4] |
McMurray J J V, Solomon S D, Inzucchi S E, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008. DOI: 10.1056/NEJMoa1911303
|
| [5] |
Packer M, Anker S D, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15): 1413-1424. DOI: 10.1056/NEJMoa2022190
|
| [6] |
Armstrong P W, Pieske B, Anstrom K J, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20): 1883-1893. DOI: 10.1056/NEJMoa1915928
|
| [7] |
McDonagh T A, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur J Heart Fail, 2022, 24(1): 3599-3726.
|
| [8] |
Heidenreich P A, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18): e895-e1032.
|
| [9] |
McMurray J J V, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction?: A redefinition of evidence-based medicine[J]. Circulation, 2021, 143(9): 875-877. DOI: 10.1161/CIRCULATIONAHA.120.052926
|
| [10] |
Hulot J S, Trochu J N, Donal E, et al. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging thera-peutic options[J]. Expert Opin Pharmacother, 2021, 22(14): 1847-1855. DOI: 10.1080/14656566.2021.1937121
|
| [11] |
Greene S J, Ezekowitz J A, Anstrom K J, et al. Medical therapy during hospitalization for heart failure with reduced ejection fraction: the VICTORIA registry[J]. J Card Fail, 2022, 28(7): 1063-1077. DOI: 10.1016/j.cardfail.2022.02.011
|
| [12] |
Anker S D, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med, 2021, 385(16): 1451-1461. DOI: 10.1056/NEJMoa2107038
|
| [13] |
Solomon S D, McMurray J J V, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098. DOI: 10.1056/NEJMoa2206286
|
| [14] |
中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYX202310002.htm
Chinese Society of Cardiology, Chinese Medical Association, Heart Rhythm Committee of Chinese Society of Biomedical Engineering. Chinese guidelines on diagnosis and manage-ment of atrial fibrillation[J]. Chin J Cardiol, 2023, 51(6): 572-618. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYX202310002.htm
|
| [15] |
Sohns C, Fox H, Marrouche N F, et al. Catheter ablation in end-stage heart failure with atrial fibrillation[J]. N Engl J Med, 2023, 389(15): 1380-1389.
|
| [16] |
Ponikowski P, Kirwan B A, Anker S D, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial[J]. Lancet, 2020, 396(10266): 1895-1904.
|
| [17] |
Kalra P R, Cleland J G F, Petrie M C, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK(IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial[J]. Lancet, 2022, 400(10369): 2199-2209.
|
| [18] |
Anker S D, Khan M S, Butler J, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis[J]. Eur J Heart Fail, 2023, 25(7): 1080-1090.
|
| [19] |
McDonagh T A, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37): 3627-3639.
|
| [20] |
Mentz R J, Garg J, Rockhold F W, et al. Ferric carboxymaltose in heart failure with iron deficiency[J]. N Engl J Med, 2023, 389(11): 975-986.
|
| [21] |
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocar-dial and Pericardial Diseases[J]. Eur J Heart Fail, 2021, 23(4): 512-526.
|
| [22] |
田庄, 张抒扬. 《转甲状腺素蛋白心脏淀粉样变诊断与治疗中国专家共识》解读及诊断路径更新[J]. 罕见病研究, 2023, 2(1): 63-69. https://www.cnki.com.cn/Article/CJFDTOTAL-HJBI202301009.htm
Tian Z, Zhang S Y. The interpretation and update of the diagnosis pathway of Chinese expert consensus on the diagnosis and treatment of transthyretin cardiac amyoidosis[J]. J Rare Dis, 2023, 2(1): 63-69. https://www.cnki.com.cn/Article/CJFDTOTAL-HJBI202301009.htm
|
| [23] |
Maurer M S, Schwartz J H, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J]. N Engl J Med, 2018, 379(11): 1007-1016.
|
| [1] | ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605 |
| [2] | TIAN Kunling, CHEN Chuanning. Notch Signaling Pathway and Congenital Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 649-654. DOI: 10.12290/xhyxzz.2023-0594 |
| [3] | ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227 |
| [4] | LI Wendao, GU Hao, WANG Wei, WU Runhui, SONG Hongmei. First Case Report of FOXN1 Haploinsufficiency in China and Literature Review[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 366-372. DOI: 10.12290/xhyxzz.2022-0040 |
| [5] | LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271 |
| [6] | ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180 |
| [7] | Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555 |
| [8] | LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. DOI: 10.3969/j.issn.1674-9081.2020.00.019 |
| [10] | Ming-sheng MA, Xü-de ZHANG, Min WEI, Shi-min ZHAO, Zheng-qing QIU. Efficacy of Low Dose Corticosteroid Therapy in Duchenne Muscular Dystrophy[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 384-388. DOI: 10.3969/j.issn.1674-9081.2014.04.006 |
| 1. |
彭晓艳，陈朝英，涂娟，高洁，李华荣. 儿童肾小管酸中毒的临床特点及诊治. 中国医刊. 2025(01): 74-78 .
| |
| 2. |
辛宇，徐俊杰，臧丽. Gitelman综合征导致糖代谢异常的相关因素分析. 中华糖尿病杂志. 2025(01): 153-161 .
| |
| 3. |
张磊，乐偲，刘岩，陈丽萌. 遗传性罕见肾脏病：精准肾脏病学的窗口. 罕见病研究. 2024(01): 1-11 .
| |
| 4. |
陈丽萌，陈朝英，张抒扬，张磊，彭晓艳，杨宏仙，简珊，樊晓红，蒋兰萍，董源，赵若环，吕宁，乐偲，涂娟. Bartter综合征诊疗中国专家共识(2023). 罕见病研究. 2024(01): 87-101 .
| |
| 5. |
周冬祺，唐诗韵，陈秋. SLC12A3基因新型纯合突变导致的Gitelman综合征合并2型糖尿病家系追踪. 中华糖尿病杂志. 2024(02): 248-253 .
| |
| 6. |
陈蓉，王曦，宋桉，王佳佳，李伟，陈适，邢小平. 青年女性，乏力，低血钾，高血糖. 协和医学杂志. 2024(02): 456-461 .
本站查看
| |
| 7. |
张洪旭，李娟娟，程炳菲，辛颖. Gitelman综合征合并库欣病1例并文献复习. 临床肾脏病杂志. 2024(04): 349-352 .
| |
| 8. |
何敏，吴加华，刘剑，赵延栋，王云卿，吴君平. Gitelman综合征合并下颌肿物1例并文献复习. 中国乡村医药. 2024(11): 51-52 .
| |
| 9. |
马韩铮，杨玲玲，刘栋，李岩. 扶阳建中针刺法治疗以矮身材为主要表现的Gitelman综合征1例. 中医儿科杂志. 2024(04): 89-91 .
| |
| 10. |
葛丹，胡雪剑. Gitelman综合征合并抑郁症1例. 中国医药科学. 2024(16): 188-190 .
| |
| 11. |
林彦琳，毕丽妨，王珏. 单等位 SLC12A3基因突变致Gitelman综合征1例的遗传学分析. 国际遗传学杂志. 2024(05): 361-365 .
| |
| 12. |
周奇，李沁原，刘雅莉，罗征秀，张卫社，陈彤，李国保，商洪才，杨克虎，张波，陈耀龙，张抒扬. 罕见病指南的制订：现状、挑战与机遇. 协和医学杂志. 2023(03): 621-628 .
本站查看
| |
| 13. |
穆妮热·阿塔吾拉，郭艳英. Gitelman综合征并发症及常见合并症的研究进展. 医学研究杂志. 2023(05): 177-179+114 .
| |
| 14. |
陈杰梅，郑跃杰，高晓洁，南晓娟. 儿童Gitelman综合征的临床特征、基因型及预后分析. 国际医药卫生导报. 2023(13): 1850-1856 .
| |
| 15. |
朱惠娟，卢琳，张晓波，吕晓虹，张丁月，陈适. 双侧岩下窦静脉采血在库欣综合征诊断中应用的专家共识(2023). 罕见病研究. 2023(03): 365-376 .
| |
| 16. |
穆妮热·阿塔吾拉，马福慧，张凯迪，王新玲，郭艳英. 2011-2020年新疆某三甲医院低钾血症病因构成及血钾特点分析. 新疆医学. 2023(06): 639-642+669 .
| |
| 17. |
阚路兰，田茂强，唐一蜜. 以腹痛为首发症状的轻型Gitelman综合征患儿1例及文献复习. 中华妇幼临床医学杂志(电子版). 2023(04): 473-479 .
| |
| 18. |
李雪峰，韩宾宾，王善龙，姜卫波，彭慧芳，姜宏卫. 不同伴随症的Gitelman综合征的诊治研究. 临床医学. 2023(11): 1-4 .
| |
| 19. |
阮希成，朱荣杰，蔡奕琪，郑浩，林程，陈宏斌. 妊娠合并Gitelman综合征1例. 福建医科大学学报. 2023(05): 380-382 .
| |
| 20. |
李文文，鲁瑾. Gitelman综合征伴胰岛素抵抗1例. 中华糖尿病杂志. 2023(Z1): 96-98 .
| |
| 21. |
陈甜甜，王晓东，余海燕. 双胎妊娠合并Gitelman综合征孕妇的妊娠结局及文献复习. 中华妇幼临床医学杂志(电子版). 2023(05): 559-568 .
| |
| 22. |
赵喆，唐彦，周婧雅，陈晓光，张磊，陈丽萌，袁涛. 50例Gitelman综合征患者临床特征和药物治疗分析. 协和医学杂志. 2022(02): 277-286 .
本站查看
| |
| 23. |
谢容融，金萍，杨幼波，张勤，熊静. 全外显子组测序诊断2例Gitelman综合征. 中南大学学报(医学版). 2022(03): 401-406 .
| |
| 24. |
陈正，吴娟，邱瑜，刘建萍. Gitelman综合征伴2型糖尿病一例报道. 中国糖尿病杂志. 2022(05): 370-374 .
| |
| 25. |
李敏，黄稳莹，张甜，郭英. 1例Gitelman综合征合并亚临床甲状腺功能减退症患者SLC12A3基因突变位点鉴定及遗传分析. 山东医药. 2022(15): 86-89 .
| |
| 26. |
朱凯瑞，李霞，李晓岚. 从1例Gitelman综合征探讨低钾血症的全科诊疗思路. 巴楚医学. 2022(02): 14-17 .
| |
| 27. |
甘佳乐，刘超，方亮娟. SLC12A3基因突变致Gitelman综合征1例. 国际遗传学杂志. 2022(06): 499-502 .
| |
| 28. |
仝天，王瑞英，张力辉，刘志红，骆建芹，赵占胜. 血镁正常的Gitelman综合征1例及文献复习. 临床荟萃. 2022(11): 1031-1036 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: